NCT Number: NCT06100705
Phase: PHASE2
Trial Summary: This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Yale University
Acronym:
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives